Lockshin Curtis 4

What Happened

• Curtis Lockshin, a director of Phio Pharmaceuticals Corp. (PHIO), received a grant of 16,600 restricted stock units (RSUs) on 2026-02-05. The reported acquisition price is $0.00, meaning no cash was paid; the award was reported on Form 4 filed 2026-02-06.
• Per the filing footnote, these RSUs will vest on the first anniversary of the grant (footnote F1). This is an equity compensation award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-05; Form 4 filed: 2026-02-06 (timely — within the usual two-business-day window).
• Transaction type/code: Award/Grant (A); reported price: $0.00; total shares granted: 16,600.
• Vesting: Shares underlying the RSUs vest on the first annual anniversary of the grant (F1).
• Ownership reporting: The filing notes that totals include shares underlying unvested RSUs (F2), and reported counts have been adjusted for prior reverse stock splits (F3).
• No indication of a 10b5-1 plan, tax withholding, or immediate sale of any shares in this filing.

Context

• RSUs are a form of deferred equity compensation: they represent the right to receive shares if/when vesting conditions are met. They do not represent immediate, tradable stock until they vest and are issued.
• Awards like this are common for directors and employees as compensation and do not by themselves signal a buy or sell decision by the insider.